GrandPharm obtained the right to commercialize BRM421,a new drug for dry eye syndrome, in mainland China, HK and Macau.
| Target Company Name |
BRM421 |
|---|---|
| Target Country |
Taiwan |
| Description | GrandPharm obtained the right to develop and commercialize BRM421 in greater China. At the same time, GrandPharm subscribed for a small amount of equity of Brimbiotech |
| Global M&A Offices |
Hollyhigh International Capital
(Global M&A China)
|
| Global M&A Advisory | Advisor to the seller |
| Further information | For further details, see: https://www.brimbiotech.com/en/brm421/ and http://www.grandpharma.cn/en/AboutUs/about.aspx |
